Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: Our experiences with 21 patients

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 249-252

  Eftekhar, Zahra ^a,c   Izadi Mood, Narges ^a   Yarandi, Fariba ^a   Shojaei, Hadi ^a   Rezaei, Zahra ^b   Mohagheghi, Saeedeh ^b  

^a Department of Gynecological Oncology ^*

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenocarcinoma; Endometrium; Megestrol acetate; Well differentiated

Indexed keywords

ACETYLSALICYLIC ACID; MEGESTROL ACETATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CURETTAGE; DRUG DOSE INCREASE; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ENDOMETRIUM TUMOR; FEMALE INFERTILITY; FERTILITY; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY; HUMANS; INFERTILITY, FEMALE; MEGESTROL ACETATE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 65649153355     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819c5372     Document Type: Article

References (15)

1. Crissman JD, Azoury RS, Barnes AE, et al. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol. 1981;57: 699-704.
2. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308.
3. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:133-138.
4. Frumovitz M, Gershenson DM. Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther. 2006;6:27-32.
5. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79:320-327.
6. Podczaski E, Mortel R. Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol. 2001;15: 469-489.
7. Kaku T, Yoshikawa H, Tsuda H, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001;167:39-48.
8. International Federation of Obstetrics and Gynecology. Annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet. 2008;28:189-193.
9. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49:2547-2559.
10. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798-2803.
11. Niwa K, Tagami K, Lian Z, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112:317-320.
12. Ota T, Yoshida M, Kimura M, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005;15:657-662.
13. Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651-657.
14. Lai CH, Huang HJ. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol. 2006;18:29-34.
15. Kamoi S, Ohaki Y, Mori O, et al. Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci-review of more than 25 biopsies from five patients. Int J Gynecol Cancer. 2008;18:1305-1314.